(S) -Crizotinib

(S) -Crizotinib is a potent and selective MTH1 (mutT homologue) inhibitor with an IC50 of 330 nM. (S) -Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models[1].

Product Specifications

CAS Number

[1374356-45-2]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Apoptosis; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/_S_-Crizotinib.html

Purity

99.81

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

NC1=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[C@H](C4=C(Cl)C=CC(F)=C4Cl)C

Molecular Formula

C21H22Cl2FN5O

Molecular Weight

450.34

Precautions

H315, H319, H320

References & Citations

[1]Huber KV, et al. Stereospecific targeting of MTH1 by (S) -crizotinib as an anticancer strategy. Nature. 2014 Apr 10;508 (7495) :222-7.|[2]Dai X, et al. (S) -crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1. J Exp Clin Cancer Res. 2017 Sep 7;36 (1) :120.